Clinical Studies| Volume 17, ISSUE 6, P1078-1090, November 1995

Download started.


Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients in acute sciatica

      This paper is only available as a PDF. To read, Please Download here.


      In this randomized, double-blind, double-dummy trial, 113 patients with acute sciatica were treated with a single 15-mg dose of meloxicam given intramuscularly (n = 54) or orally (n = 59). There was a significant improvement in induced pain (as measured by using the straight-leg-raising test) in both treatment groups at 60 minutes (P < 0.005), and there was a significant difference in favor of the intramuscular formulation in terms of the time to maximum improvement of induced pain (P = 0.01). Changes in spontaneous pain were similar in both treatment groups and were significant versus baseline (P < 0.01) at 30 minutes after study drug administration. Global efficacy evaluations by both the patients and investigators confirmed that meloxicam 15 mg in an intramuscular or oral formulation was effective in relieving pain in patients with acute sciatica. Meloxicam was generally well tolerated, and the local tolerability of the intramuscular injection was found to be excellent on the basis of both clinical evaluation and assessment of creatine phosphokinase levels.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Frymoyer JW
        Back pain and sciatica.
        NEJM. 1988; 318: 291-300
        • Rosa A
        • Delcour J
        Mononeuropathies: Névralgie cervicobrachiale, névralgie sciatique. Etiologie, diagnostique, traitement.
        Rev Prat. 1991; 41: 275-277
      1. Narjes H, Bluhmki E, Huskisson EC. Efficacy and tolerance of UHAC-62 XX in daily doses of 15, 30 and 60 mg p.o. and piroxicam in a daily dose of 20 mg p.o. in patients with rheumatoid arthritis. Data on file, Boehringer Ingelheim, Dr. Karl Thomae GmbH, Biberach/Riss, Germany, 1992.

        • Lund B
        • Distel M
        • Bluhmki E
        A doubleblind, placebo-cointrolled study of three different doses of meloxicam in patients with osteoarthritisof the knee.
        Scand J Rheumatol. 1994; (Abstract no. 117)
        • Linden B
        • Distel M
        • Bluhmki E
        A double-blind randomised comparison of meloxicam and piroxicam in patients with osteo-arthritis of the hip.
        Scand. J. Rheumatol. 1994; (Abstract no. 182)
        • Stei P
        • Püschner H
        Intramuscular tolerance of meloxicam compraed to piroxicam and diclofenac in rabbits.
        Scand J Rheumatol. 1994; (Abstract no. 109)
        • Engelhardt G
        Meloxicam inhibits preferentially COX-2.
        Eur J Clin Pharmacol. 1994; 47: A98
      2. Engelhardt G, Homma D, Schlegel K, Schnitzler CHR. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent. Inflamm Res. In press.

        • Patoia L
        • Santucci L
        • Furno P
        • et al.
        Gastrointestinal (GI) tolerability of meloxicam, piroxicam, and placebo by comparison of fecal blood loss (FBL), upper gastrointestinal endoscopy (UE) and symptoms evaluation.
        Rheumatol Eur. 1995; 24 (Abstract no. E258)
      3. Narjes H, Nehmiz G, Busch U. Tolerability and pharmacokinetics of meloxicam (UHAC-62 XX) as a single intramuscular injection in ascending doses of 5, 10, 20 and 30 mg in healthy volunteers. Data on file, Boehringer Ingelheim, Dr. Karl Thomae GmbH, Biberach/Riss, Germany, 1990.

        • Laufen H
        • Leitold M
        The effect of activated charcoal on the bioavailability of piroxicam in man.
        Int J Clin Pharmacol Ther Toxicol. 1986; 24: 48-52
        • Nilsen OG
        Clinical pharmacokinetics of tenoxicam.
        Clin Pharmacokin. 1994; 26: 16-43
      4. Busch U, Bozler B, Heinzel G, Schmid J. Pharmacokinetics of 14C labelled UHAC-62 XX (meloxicam) in man. Data on file, Boehringer Ingelheim, Dr. Karl Thomae GmbH, Biberach/Riss, Germany, 1989.

      5. Türck D. Dose-proportionality of UH.AC 62 XX (meloxicam) in humans. A review. Data on file, Dr. Karl Thomae GmbH, Biberach/Riss, Germany, 1993.

        • Engelhardt G
        • Trummlitz G
        Biological activity of the main metabolites of meloxicam.
        Drugs Exp Clin Res. 1990; 16: 53-56
        • Valat JP
        • Jacquart F
        Au début de la sciatique intérêt respectif et date de réalisation des examens d'imagerie autres que les radiographies standard. Arguments cliniques qui nécessitent de faire rapidement un diagnostic différentiel.
        Rachis. 1991; 3: 23-26
        • Vaccarino V
        • Sirtori CR
        • Bufalino L
        Local and systemic tolerability of piroxicam after intramuscular administration in healthy volunteers.
        Curr Ther Res. 1989; 45: 1-13